ArticleCancers2025
Oncologic Outcomes of Young Breast Cancer Patients According to Tumor Biology.
Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Correlates of Ki-67 proliferation index in a cohort of women with suspected breast cancer in Lusaka, Zambia.PLOS global public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesYoung women frequently present with more aggressive breast cancer tumors. This retrospective study analyzed the oncological outcomes of patients under the age of 40 according to the tumor biology.
methodsGroup comparisons were performed via the log-rank test. Recurrence and survival rates are presented according to the Kaplan-Meier method.
resultsIn total, 88 women (mean age 36) were included, but two presented with bilateral cancer, resulting in 90 tumors. Triple-negative carcinoma was most common, with 26.7% (n = 24); 11.1% (n = 10) were luminal A; 23.3% (n = 21) were luminal B HER2-negative; 15.6% (n = 14) were luminal B HER2-positive; and 6.7% (n = 6) were HER2-positive (non-luminal). Moreover, 26.1% (n = 23) of patients experienced recurrence (mean 40 months), with the highest recurrence rate in the HER2-positive (50%) and triple-negative (30.4%) groups. The 3- and 5-year recurrence-free survival rates were 84.9% and 77.3%, and the overall survival rates were 93.1% and 90.3%, respectively. No statistically significant differences in oncological outcomes were observed (
conclusionsThe results show that young women tend to have triple-negative and fast-growing breast carcinomas, with worse overall survival in the triple-negative group. More research is needed on the pathomechanisms of breast cancer development in young women, especially those leading to disease progression and resistance to therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.